Daiichi Sankyo 4568.T
Daiichi Sankyo is a global pharmaceutical company that develops and commercializes medicines, with a primary focus on oncology, where its flagship drug Enhertu is a growth pillar. Daiichi Sankyo shows solid financial health (net cash, DN/EBITDA -0.44) and an attractive dividend (3.53%), but its earnings growth is negative (-18.10%) and free cash flow conversion is very weak (-62.00%), which weighs on its quality and valuation. Enhertu's success in new indications (lung cancer) and NHS approval are positive catalysts, although momentum is very negative (-20.32%).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Daiichi Sankyo is a global pharmaceutical company that develops and commercializes medicines, with a primary focus on oncology, where its flagship drug Enhertu is a growth pillar. Daiichi Sankyo shows solid financial health (net cash, DN/EBITDA -0.44) and an attractive dividend (3.53%), but its earnings growth is negative (-18.10%) and free cash flow conversion is very weak (-62.00%), which weighs on its quality and valuation. Enhertu's success in new indications (lung cancer) and NHS approval are positive catalysts, although momentum is very negative (-20.32%).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.9 |
| Quality / Moat | 5.7 |
| Valuation | 4.2 |
| Growth | 5.0 |
| Dividend | 7.8 |
| Momentum | 1.0 |
| Risk & Context | 4.7 |
OVERALL SCORE: 5.3/10
Context and risks
Moderate regulatory risk in Japan and exposure to drug approvals in key markets. However, the recent approval of Enhertu in the NHS reduces short-term regulatory uncertainty.
News considered in the analysis
- AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England — Aprobación de Enhertu para uso en el NHS inglés: amplía el acceso a un mercado clave y refuerza la posición del fármaco estrella, con impacto positivo en ingresos futuros.
- AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success — Éxito en fase III de Enhertu en cáncer de pulmón HER2: amplía las indicaciones del fármaco y abre un nuevo mercado significativo, material para el crecimiento.
- AstraZeneca Gains as Enhertu Clears England's Value Gate — Supera la evaluación de valor del NICE, confirmando la aprobación y el acceso al mercado inglés; refuerza la noticia anterior.
- Daiichi Sankyo Company (TSE:4568) Could Be 31% Below Fair Value As Legal Risk Clears — La resolución de un riesgo legal reduce la incertidumbre y podría justificar una revalorización, aunque la estimación de valor razonable es subjetiva.
- AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market? — Análisis especulativo sobre el mercado de cáncer de mama, sin información nueva y concreta sobre Daiichi Sankyo.
Verdict: Hold: fundamentals are mixed and momentum is weak, but Enhertu's progress and a solid cash position offer medium-term recovery potential.
Main risk: The sharp decline in earnings (-18.10%) and poor free cash flow conversion (-62.00%) indicate the business is under pressure, and Enhertu's success may not be enough to reverse the trend if competition in oncology intensifies.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →